<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Myelodysplastic syndromes/neoplasms (MDS): Management of hematologic complications in lower-risk MDS</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mikkael A Sekeres, MD, MS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Uwe Platzbecker, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2100015"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous group of hematologic malignancies that manifest as cytopenias (anemia, neutropenia, and/or thrombocytopenia) and abnormal cellular maturation, with variable rates of bone marrow failure and progression to acute myeloid leukemia (AML). Patients with MDS often have symptomatic anemia, infections related to neutropenia, and/or bleeding associated with thrombocytopenia. Much of the morbidity and death with MDS is due to consequences of cytopenias rather than transformation to AML. </p><p>Cases of MDS are diagnosed and classified according to specific molecular and genetic abnormalities using a contemporary classification system, as described separately. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.) </p><p>All patients require attention to potential hematologic complications of MDS. Other aspects of management are guided by the prognostic category (ie, lower-risk MDS versus higher-risk MDS), defined using a molecular-based model, such as the Molecular International Prognostic Scoring System (IPSS-M), as described separately. (See  <a class="medical medical_review" href="/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults", section on 'Mutation-based models'</a>.)</p><p>This topic reviews management of hematologic complications for patients with lower-risk MDS.</p><p>Other aspects of MDS management are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16122.html" rel="external">"Overview of the treatment of myelodysplastic syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16121.html" rel="external">"Treatment of high or very high risk myelodysplastic syndromes"</a>.)</p><p></p><p class="headingAnchor" id="H3569437048"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Evaluation for hematologic complications of MDS and alternative causes of cytopenias. </p><p>Details of evaluation, diagnosis, and classification of MDS are presented separately. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>History</strong> – Symptoms related to cytopenias (eg, fatigue, dyspnea, infections, bleeding/bruising). </p><p></p><p class="bulletIndent1">Assessment for other potential causes of cytopenias, including medications, blood loss, infections, hemolysis, renal insufficiency, nutritional deficiencies, thyroid dysfunction, autoimmune disorders, and other conditions that can contribute to cytopenias, should be evaluated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical examination</strong> – Examination should note findings related to anemia (eg, pallor, tachycardia, tachypnea), occult blood loss, bleeding or bruising, splenomegaly, and evidence of infections. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory studies</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hematology</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Complete blood count (CBC) with differential leukocyte count</p><p class="bulletIndent3"><span class="glyph">-</span>Review of the blood smear</p><p class="bulletIndent3"><span class="glyph">-</span>Reticulocyte count and reticulocyte production index (RPI) (<a class="calc calc_professional" href="/d/html/90441.html" rel="external">calculator 1</a>) to help distinguish impaired red blood cell (RBC) production versus blood loss or hemolysis</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemistries</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Basic metabolic panel, kidney function, and liver function tests, including lactate dehydrogenase (LDH).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Iron studies, including serum iron, transferrin, ferritin.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Serum erythropoietin (EPO).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Other laboratory tests, including thyroid function tests, folate, vitamin B12, serum copper, and viral serologies (eg, hepatitis B, hepatitis C, human immunodeficiency virus [HIV]), are guided by clinical and laboratory findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone marrow examination</strong> – Bone marrow aspirate and biopsy are key components of the initial diagnosis and classification of MDS, as discussed separately. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)", section on 'Bone marrow examination'</a>.) </p><p></p><p class="bulletIndent1">Repeat bone marrow examination may be useful if there is suspicion of transformation to acute myeloid leukemia or other conditions that may exacerbate cytopenias. </p><p></p><p>The extent of cytopenias are features in most prognostic models of MDS, as discussed separately. (See  <a class="medical medical_review" href="/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults"</a>.)</p><p class="headingAnchor" id="H2956510909"><span class="h1">ANEMIA</span><span class="headingEndMark"> — </span>Anemia is the most common cytopenia in patients with MDS. More than three-quarters of patients with MDS have anemia, one-half of whom have hemoglobin (Hb) &lt;10 g/dL [<a href="#rid1">1</a>]. Patients with MDS tend to be older (ie, median age &gt;65 years at presentation) and/or have comorbid medical problems, so factors other than MDS may contribute to anemia.</p><p>Anemia can manifest as fatigue, weakness, exercise intolerance, loss of appetite/weight loss, angina, dizziness, dyspnea, headache, cognitive impairment, or an altered sense of wellbeing. Clinical manifestations of anemia in adults are discussed separately. (See  <a class="medical medical_review" href="/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults", section on 'Correlation with symptoms'</a>.)</p><p>Management of anemia in patients with MDS is guided by the degree of anemia-associated symptoms and the serum level of erythropoietin (EPO). </p><p>In general, management of anemia is not determined by the MDS subtype. However, patients who have MDS with deletion of chromosome 5 (with or without one additional chromosomal abnormality, except -7/del[7q]) or MDS with ring sideroblasts/<em>SF3B1 </em>mutation may be candidates for distinctive treatments, as discussed separately. (See  <a class="medical medical_review" href="/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Chromosome 5q deletion'</a> and  <a class="medical medical_review" href="/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'MDS with ring sideroblasts'</a>.)</p><p class="headingAnchor" id="H4059021430"><span class="h2">Management of asymptomatic patients</span><span class="headingEndMark"> — </span>We do not treat anemia based on the level of Hb alone in asymptomatic patients, as there is no evidence that treating asymptomatic anemia affects outcomes of patients with MDS.</p><p>However, we transfuse red blood cells (RBCs) if bleeding or the rate of decline of Hb suggests that the patient will soon become symptomatic, especially if there are comorbid cardiac, pulmonary, or neurologic conditions. RBC transfusion for such patients is discussed below. (See <a class="local">'Red blood cell transfusions'</a> below.)</p><p class="headingAnchor" id="H4268473717"><span class="h2">Symptomatic patients</span><span class="headingEndMark"> — </span>We stratify anemia management in symptomatic patients based on the level of serum EPO.</p><p class="headingAnchor" id="H1233207528"><span class="h3">Serum erythropoietin ≤500 mU/mL</span><span class="headingEndMark"> — </span>For patients with serum EPO ≤500 mU/mL, we recommend treatment with an erythropoiesis-stimulating agent (ESA) rather than RBC transfusions alone. </p><p>ESAs were more effective than placebo for achieving transfusion independence and raising the level of Hb in two randomized trials, and they were associated with improved quality of life and prolonged survival in some observational studies. There is little toxicity associated with ESAs in this setting. RBC transfusions can be used as the sole treatment of anemia, but repeated RBC transfusions may cause complications from chronic transfusion therapy (eg, alloimmunization, iron overload), as discussed below. (See <a class="local">'Red blood cell transfusions'</a> below.)</p><p>Although patients with MDS with certain del(5q) abnormalities or MDS with ring sideroblasts/mutated <em>SF3B1</em> are managed distinctly, a trial of an ESA is acceptable in such patients who have anemia-related symptoms and serum EPO ≤500 mU/mL. Other aspects of management of these MDS subtypes are discussed separately. (See  <a class="medical medical_review" href="/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Special patient populations'</a>.)</p><p class="headingAnchor" id="H182411281"><span class="h4">Choice of erythropoiesis-stimulating agent</span><span class="headingEndMark"> — </span>Treatment with either recombinant <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">epoetin alfa</a> or <a class="drug drug_general" data-topicid="8662" href="/d/drug information/8662.html" rel="external">darbepoetin alfa</a> is acceptable for lower-risk MDS with EPO ≤500 mU/mL, based on similar efficacy and adverse effects (AEs). </p><p>Patients should be evaluated for thromboembolic risk prior to ESA therapy, and hypertension should be controlled before and during treatment. </p><p>Some experts consider an ESA plus <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> (granulocyte-colony stimulating factor [G-CSF]) acceptable for initial treatment. The administration of ESA plus filgrastim is discussed below. (See <a class="local">'Inadequate response to erythropoiesis-stimulating agent'</a> below.) </p><p>Outcomes of treatment with an ESA, with or without G-CSF, are presented below. (See <a class="local">'Outcomes'</a> below.)</p><p class="headingAnchor" id="H1743918909"><span class="h4">Administration and toxicity</span><span class="headingEndMark"> — </span>Various doses and schedules of ESAs have been used for treatment of anemia in patients with MDS. We generally begin treatment with either:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Epoetin alfa</strong><strong> </strong>–<strong> </strong>Recombinant human epoetin 40,000 to 60,000 units/week subcutaneously; this can be administered once per week or in divided doses (eg, two injections per week).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Darbepoetin alfa</strong> – 150 to 300 mcg subcutaneously every other week; some experts begin treatment with doses up to 500 mcg every other week.</p><p></p><p class="bulletIndent1">Further details of ESA regimens  (<a class="graphic graphic_table graphicRef59470" href="/d/graphic/59470.html" rel="external">table 1</a>) and additional aspects of care, including iron repletion, are provided separately. (See  <a class="medical medical_review" href="/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on 'Clinical use of ESAs in cancer patients'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">Epoetin alfa</a> is approved by the European Medicines Agency (EMA) for treatment of anemia in patients with lower-risk MDS with a serum EPO level ≤200 mU/mL; the manufacturer withdrew its request to the EMA for approval of darbepoetin for treating anemia in MDS. Neither epoetin alfa nor <a class="drug drug_general" data-topicid="8662" href="/d/drug information/8662.html" rel="external">darbepoetin alfa</a> is approved by the US Food and Drug Administration (FDA) for treatment of anemia in patients with MDS, despite their widespread use. </p><p></p><p class="bulletIndent1">Use of ESAs is recommended by international clinical practice guidelines based on the large body of evidence demonstrating their effectiveness in lower-risk MDS. ESA use in MDS is supported by the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (ESMO), and European LeukemiaNet [<a href="#rid2">2-6</a>]. It should be noted that patients with low- or intermediate-1-risk MDS are an <strong>exception</strong> to the general recommendation from ASH and ASCO to avoid ESAs for the treatment of anemia associated with malignancy in patients who are not receiving concurrent myelosuppressive chemotherapy [<a href="#rid2">2,3</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – ESAs can exacerbate hypertension, but there is no persuasive evidence that they increase thromboembolic complications or mortality in patients with MDS (as has been shown in other settings) or increase the rate of progression to acute myeloid leukemia (AML).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Exacerbation of hypertension</strong> – Hypertension should be controlled before and during therapy with ESAs. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombotic risk</strong> – There is no evidence that ESAs increase thromboembolic risk in patients with MDS. A review of 5673 patients with MDS in a United States Medicare database reported no difference in thrombosis rates between patients treated with an ESA compared with those who did not receive an ESA in the prior 12 weeks [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent2">Nevertheless, before beginning ESA therapy, the patient should be evaluated for a history of prior thromboembolism, heritable or acquired thrombophilic conditions, prolonged immobility, and other risk factors, as discussed separately. (See  <a class="medical medical_review" href="/d/html/2799.html" rel="external">"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer", section on 'Issues related to thromboembolic risk'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Progression to acute myeloid leukemia</strong> – There is no clear evidence that ESAs are associated with increased transformation to AML. Rates of progression are low with both <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">epoetin alfa</a> and <a class="drug drug_general" data-topicid="8662" href="/d/drug information/8662.html" rel="external">darbepoetin alfa</a> and are comparable with rates in patients who receive supportive care alone [<a href="#rid8">8-10</a>]. </p><p></p><p class="headingAnchor" id="H3853662611"><span class="h4">Response to erythropoiesis-stimulating agent therapy</span><span class="headingEndMark"> — </span>We assess transfusion needs and Hb after six to eight weeks of ESA therapy. </p><p>We treat with an ESA for ≥16 weeks before concluding that therapy was ineffective. We do not continue treatment for &gt;6 months if no response was observed by then.</p><p>Initially, transfusions may be needed to manage symptoms while awaiting an erythroid response, but we then adjust ESA administration to the lowest level that enables avoidance of further RBC transfusions. Median time to erythroid response is five weeks (range, four to nine weeks), and duration of response ranges from 8 to &gt;48 months [<a href="#rid8">8,11-17</a>]. </p><p>We judge erythroid response to ESAs as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adequate response</strong> – Hb 10 to 12 g/dL, Hb rise by ≥1.5 gm/dL, and/or reduced transfusion requirements.</p><p></p><p class="bulletIndent1">Hematologic responses to treatment should follow the revised International Working Group (IWG) 2018 criteria [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1">Further management of patients with an adequate response to ESA therapy is discussed below. (See <a class="local">'Adequate response to erythropoiesis-stimulating agent'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inadequate response</strong> – Not meeting the criteria for an adequate response (described above) after ≥16 weeks of ESA treatment.</p><p></p><p class="bulletIndent1">Further management of patients with an inadequate response is discussed below. (See <a class="local">'Inadequate response to erythropoiesis-stimulating agent'</a> below.)</p><p></p><p class="headingAnchor" id="H3541218786"><span class="h5">Adequate response to erythropoiesis-stimulating agent</span><span class="headingEndMark"> — </span>For patients with an adequate response to ESA therapy, we continue treatment and adjust administration to minimize transfusions and maintain Hb 10 to 12 g/dL.</p><p>If the rise of Hb is sufficient to avoid transfusions or if it increases ≥1.5 g/dL in any two-week period, the dose of <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">epoetin alfa</a> can be reduced by 25 percent, or the dose of <a class="drug drug_general" data-topicid="8662" href="/d/drug information/8662.html" rel="external">darbepoetin alfa</a> can be reduced by 40 percent. Less frequent dosing is an acceptable alternative to dose reduction.</p><p>For patients who subsequently lose their response to ESA treatment, we manage as per an inadequate initial response. (See <a class="local">'Inadequate response to erythropoiesis-stimulating agent'</a> below.)</p><p class="headingAnchor" id="H2934846890"><span class="h5">Inadequate response to erythropoiesis-stimulating agent</span><span class="headingEndMark"> — </span>For patients with an inadequate response (ie, Hb rise &lt;1.5 g/dL or no improvement in transfusion frequency) after ≥16 weeks of treatment, some experts add <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">filgrastim</a> to the ESA.</p><p>Some experts consider adding <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> to ESA therapy as an acceptable alternative approach. While some patients may favor lenalidomide because it is an oral agent, this approach may exacerbate thromboembolic risk and/or other cytopenias (ie, neutropenia or thrombocytopenia). </p><p>Only small studies have reported effects of adding G-CSF to ESA therapy after an inadequate response to an ESA alone:</p><p class="bulletIndent1"><span class="glyph">●</span>Addition of G-CSF to <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">epoetin alfa</a> was associated with a better response in patients who did not initially respond adequately or who had only a transient response to epoetin alone [<a href="#rid19">19</a>]. Among 27 patients who did not respond adequately to epoetin alfa, 22 percent had an erythroid response when G-CSF 1 mcg/kg per day was added.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among 30 patients who had an inadequate response to epoetin beta alone, addition of G-CSF 300 mcg subcutaneously twice weekly was associated with an erythroid response in 44 percent [<a href="#rid20">20</a>].</p><p></p><p>We monitor the response to ESA plus G-CSF as described above. (See <a class="local">'Response to erythropoiesis-stimulating agent therapy'</a> above.)</p><p class="headingAnchor" id="H3462974464"><span class="h4">Outcomes</span><span class="headingEndMark"> — </span>ESAs can reduce transfusion needs and ameliorate anemia in approximately one-half of patients with lower-risk MDS, and there is some evidence that these agents can improve overall survival (OS) and quality of life (QOL). The benefits and AEs associated with <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">epoetin alfa</a> and <a class="drug drug_general" data-topicid="8662" href="/d/drug information/8662.html" rel="external">darbepoetin alfa</a> do not differ significantly, but no randomized trials have directly compared them for patients with MDS and symptomatic anemia.</p><p>Numerous studies report erythroid responses in one-quarter to three-quarters of patients in this setting, but reports vary widely. Differences in outcomes among studies are due, in part, to various inclusion criteria, treatment regimens, and response criteria [<a href="#rid8">8</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systematic review</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A systematic review of 35 studies reported that ESA treatment was associated with clinical benefits and very few safety concerns [<a href="#rid8">8</a>]. There was consistent improvement in erythroid response across studies, regardless of prior ESA treatment; responses ranged from 45 to 73 percent in ESA-naïve patients and 25 to 75 percent in patients with prior ESA exposure. There was no clear difference in responses to <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">epoetin alfa</a> and <a class="drug drug_general" data-topicid="8662" href="/d/drug information/8662.html" rel="external">darbepoetin alfa</a>. Several of the studies reported improved OS, some showed improved QOL, and there was no evidence of an increased rate of progression to AML.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Randomized trials of erythropoiesis-stimulating agents versus placebo or transfusion support</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A phase 3 trial reported that <a class="drug drug_general" data-topicid="8662" href="/d/drug information/8662.html" rel="external">darbepoetin alfa</a> was more effective than placebo for achieving transfusion independence among 147 patients with lower-risk MDS, hemoglobin ≤10 g/dL, low transfusion burden, and serum EPO ≤500 mU/mL [<a href="#rid21">21</a>]. Patients were randomly assigned (2:1) to 24 weeks of darbepoetin alfa 500 mcg subcutaneously or placebo every three weeks. Compared with placebo, darbepoetin reduced the percentage of patients who needed transfusions in weeks 5 to 24 (36 versus 59 percent) and improved erythroid response at 24 weeks (15 versus 0 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An open-label randomized trial (EPOANE 3021) reported that <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">epoetin alfa</a> 450 international units/kg subcutaneously each week was superior to placebo for achieving an erythroid response among 130 patients with lower-risk MDS, symptomatic anemia, Hb ≤10 g/dL, transfusion dependence (≤4 RBC units within eight weeks of randomization), and baseline EPO &lt;500 mU/mL [<a href="#rid22">22</a>]. Epoetin alfa achieved 32 percent erythroid response at week 24, compared with 4 percent with placebo; there was no difference in rates of progression to AML. Responses were only seen in patients with EPO &lt;200 mU/mL.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Compared with transfusion support alone, <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">epoetin alfa</a> alone achieved more erythroid responses (36 versus 10 percent), but no difference in OS, in a phase 3 trial of 110 patients with MDS [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">Epoetin alfa</a> plus G-CSF achieved superior erythroid response compared with transfusions alone in a phase 3 trial in 60 patients [<a href="#rid23">23</a>]. At 12 weeks, 42 percent of patients who received G-CSF plus epoetin alfa had an erythroid response compared with none who received transfusions. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other outcomes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Survival</strong> – Some studies reported that ESA treatment was associated with improved OS. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>ESA treatment was associated with improved OS in a retrospective study that compared 284 patients treated with an ESA with 225 patients who received only supportive care [<a href="#rid17">17</a>]. Five-year OS was 64 percent in patients treated with an ESA, compared with 39 percent with supportive care alone (hazard ratio [HR] 0.61 [95% CI 0.44-0.83]).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Subset analysis of a prospective study reported that OS was superior in ESA-responsive patients compared with nonresponders (six versus two years, respectively) [<a href="#rid19">19</a>]. A retrospective study reported that treatment with an ESA plus G-CSF was associated with improved survival compared with supportive care alone (HR 0.61 [95% CI 0.44-0.83]) [<a href="#rid9">9</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Mortality was 2 percent after 48 weeks of darbepoetin therapy in one phase 3 trial, but none of the fatal events were considered treatment related [<a href="#rid21">21</a>]. In another phase 3 trial, <a class="drug drug_general" data-topicid="8662" href="/d/drug information/8662.html" rel="external">darbepoetin alfa</a> was associated with higher mortality at 52 weeks (8 versus 2 percent) than placebo, but none of the deaths were attributed to the ESA [<a href="#rid22">22</a>]. <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">Epoetin alfa</a> did not achieve higher OS at 6 or 12 months than standard care in another phase 3 trial, but there was a trend toward higher OS at last follow-up (28 versus 16 percent at a median of nearly six years follow-up) [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Quality of life</strong> – Some studies have reported improved QOL with ESA treatment.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>There was no significant difference in QOL with <a class="drug drug_general" data-topicid="8662" href="/d/drug information/8662.html" rel="external">darbepoetin alfa</a> compared with placebo, but differences may have been obscured because patients in the control arm were transfused to maintain Hb &gt;8 g/dL [<a href="#rid21">21</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Another phase 3 trial reported no difference in QOL (measured by Functional Assessment of Cancer Therapy [FACT]-Anemia score) between <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">epoetin alfa</a> plus G-CSF compared with transfusion support alone [<a href="#rid23">23</a>]. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Various single-arm studies reported improved QOL in association with ESA therapy [<a href="#rid13">13,15,24-27</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial treatment with erythropoiesis-stimulating agent plus granulocyte-colony stimulating factor</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A meta-analysis reported that initial treatment with G-CSF or granulocyte-macrophage colony-stimulating factor (GM-CSF) added to standard-dose <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">epoetin alfa</a> (a dose of 30,000 to 40,000 units weekly) was associated with inferior responses compared with higher-dose epoetin alfa alone (ie, 60,000 to 80,000 units weekly) [<a href="#rid28">28</a>]. Higher-dose epoetin alfa was associated with higher erythroid response (65 percent) compared with either standard-dose epoetin alfa plus G-/GM-CSF (51 percent) or standard-dose epoetin alfa alone (49 percent). In the subset of patients who were transfusion dependent, addition of G-CSF/GM-CSF was not associated with lower rates of transfusion.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>There was no significant difference in erythroid response between patients treated with an ESA plus G-CSF (58 percent) compared with an ESA alone (66 percent) in a retrospective analysis of 403 patients [<a href="#rid17">17</a>]. The frequency of AML progression was similar in both cohorts. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Other studies reported similar rates of erythroid response among patients treated with an ESA, whether with or without G-CSF [<a href="#rid9">9,24,29</a>]. </p><p></p><p class="headingAnchor" id="H1060825447"><span class="h4">Serum erythropoietin &gt;500 mU/mL</span><span class="headingEndMark"> — </span>For symptomatic patients with EPO &gt;500 mU/mL, we stratify treatment according to the likelihood of a response to immunosuppression (based on clinical and pathologic features). </p><p class="headingAnchor" id="H4087630055"><span class="h5">Assess likelihood of response to immunosuppressive therapy</span><span class="headingEndMark"> — </span>We estimate the likelihood that a patient will respond to immunosuppressive therapy (IST) using the following criteria [<a href="#rid30">30,31</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Age ≤60 years <strong>and</strong> &lt;5 percent marrow blasts</p><p></p><p class="bulletIndent1"><strong>or</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypocellular marrow, paroxysmal nocturnal hemoglobinuria clone positivity, <strong>or</strong> a<em> STAT3</em> mutant cytotoxic T cell clone</p><p></p><p class="headingAnchor" id="H3696940050"><span class="h5">Likely to respond to immunosuppressive therapy</span><span class="headingEndMark"> — </span>For patients with EPO &gt;500 mU/mL who are more likely to respond to immunosuppression, we suggest IST using <a class="drug drug_general" data-topicid="9107" href="/d/drug information/9107.html" rel="external">horse antithymocyte globulin</a>, with or without cyclosporin A, and with or without <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a>. </p><p>No studies have compared various IST regimens for patients with MDS. The suggestion for adding the thrombopoietin mimetic, <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a>, is based on studies of adults with severe aplastic anemia [<a href="#rid32">32</a>]. Addition of eltrombopag to IST in severe aplastic anemia was associated with improved hematologic response and overall response rate (ORR) compared with a historical cohort; there was no increase in clonal evolution. Another study reported similar rates of two-year OS, complete response (CR), and time to response when IST (antithymocyte globulin, <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a>, cyclosporin A, and G-CSF) was administered with or without addition of eltrombopag [<a href="#rid33">33</a>].</p><p>Details of administration, AEs, and outcomes with IST in patients with severe aplastic anemia are discussed separately. (See  <a class="medical medical_review" href="/d/html/7158.html" rel="external">"Treatment of aplastic anemia in adults", section on 'Triple IST (hATG, CsA, EPAG)'</a>.)</p><p><a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">Eltrombopag</a> is not approved by the FDA or the EMA for use in patients with MDS.</p><p class="headingAnchor" id="H3486268477"><span class="h5">Unlikely to respond to immunosuppressive therapy</span><span class="headingEndMark"> — </span>For patients who are less likely to respond to IST, we treat the underlying MDS according to the MDS prognostic category and disease subtype, as described separately. (See  <a class="medical medical_review" href="/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Symptomatic MDS'</a> and  <a class="medical medical_review" href="/d/html/16121.html" rel="external">"Treatment of high or very high risk myelodysplastic syndromes"</a>.)</p><p class="headingAnchor" id="H502321950"><span class="h2">Treatments</span></p><p class="headingAnchor" id="H9725060"><span class="h3">Red blood cell transfusions</span><span class="headingEndMark"> — </span>RBC transfusions can provide prompt relief for symptomatic patients and improve QOL, but they may be associated with fluid overload, transfusion reactions, and/or alloimmunization, and heavily transfused patients may develop iron overload.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion threshold</strong> – Transfusions should be used primarily to relieve symptoms related to anemia and to prevent complications in patients who have significant cardiovascular, pulmonary, or neurologic comorbidities. </p><p></p><p>The threshold for transfusion varies with age, symptoms, and medical comorbidities. Although there is no consensus, many centers transfuse asymptomatic patients with Hb ≤8 g/dL [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Thresholds for specific patient populations'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukoreduction</strong> – Leukoreduced blood products should be used to decrease risks for platelet isosensitization, febrile transfusion reactions, cytomegalovirus (CMV) and other viral infections, and immunosuppression. </p><p></p><p class="bulletIndent1">CMV-negative or leukapheresis blood products should be used, whenever possible, for recipients who are CMV negative. (See  <a class="medical medical_review" href="/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Pre-storage leukoreduction'</a>.)</p><p></p><p class="bulletIndent1">Administration of CMV-negative, irradiated blood products is of special importance for patients who are candidates for hematopoietic cell transplantation (HCT). (See  <a class="medical medical_review" href="/d/html/7939.html" rel="external">"Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Irradiation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – AEs associated with chronic transfusion include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transfusion reactions </p><p class="bulletIndent2"><span class="glyph">•</span>Infections </p><p class="bulletIndent2"><span class="glyph">•</span>Alloimmunization </p><p class="bulletIndent2"><span class="glyph">•</span>Iron overload </p><p></p><p class="bulletIndent1">AEs associated with RBC transfusions are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/95132.html" rel="external">"Approach to the patient with a suspected acute transfusion reaction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Iron overload</strong> – Chronic transfusion therapy may be associated with iron overload and resultant organ toxicity, but this is predominantly a problem for patients who have received &gt;50 units of RBCs and who have longer life expectancy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Evaluation</strong> – We generally measure serum ferritin before or early in chronic transfusion therapy and monitor ferritin periodically in a patient who has received &gt;20 units of RBC transfusion. </p><p></p><p class="bulletIndent2">Assessment of iron stores with magnetic resonance imaging (MRI) or a liver biopsy is discussed separately. (See  <a class="medical medical_review" href="/d/html/7118.html" rel="external">"Management of thalassemia", section on 'Assessment of iron stores and initiation of chelation therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chelation therapy</strong> – There is no demonstrated clinical benefit from iron chelation in patients with MDS and no consensus chelation regimen. </p><p></p><p class="bulletIndent2">We consider iron chelation therapy after transfusion of approximately 50 units of RBCs in a patient with lower-risk MDS and long life expectancy, or if MRI or a liver biopsy suggests substantial liver iron overload. A decision to pursue chelation therapy is personalized and should weigh the expense, inconvenience, and AEs (eg, gastrointestinal symptoms, impaired kidney function) against potential benefits. The choice of chelation agent and regimen is discussed separately. (See  <a class="medical medical_review" href="/d/html/7146.html" rel="external">"Iron chelators: Choice of agent, dosing, and adverse effects"</a>.)</p><p></p><p class="bulletIndent2">A multicenter trial (TELESTO) that randomly assigned patients with lower-risk MDS to oral <a class="drug drug_general" data-topicid="8794" href="/d/drug information/8794.html" rel="external">deferasirox</a> versus placebo closed prematurely due to lagging patient enrollment; we judge that no conclusions can be drawn from this trial because of changes in trial design, study objectives, and patient accrual [<a href="#rid35">35</a>]. </p><p></p><p class="headingAnchor" id="H7195992"><span class="h3">Erythropoiesis-stimulating agents</span><span class="headingEndMark"> — </span>Administration, toxicity, and outcomes with ESA therapy for patients with MDS and symptomatic anemia are presented above. (See <a class="local">'Serum erythropoietin ≤500 mU/mL'</a> above.)</p><p class="headingAnchor" id="H1310987371"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>Other agents have been associated with improvements in anemia in selected patients with MDS, including those with MDS with del(5q) and MDS with ring sideroblasts/<em>SF3B1</em> mutation. </p><p class="headingAnchor" id="H1452748236"><span class="h4">Lenalidomide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> can reduce transfusion needs in patients with MDS with del(5q) and in a subset of patients with non-(del5q), lower-risk MDS. </p><p><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> is approved by the FDA and the EMA for treatment of transfusion-dependent MDS with del(5q). </p><p><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> may cause thrombocytopenia and neutropenia, increase risk of arterial and venous thrombosis/pulmonary embolism, and is associated with embryo-fetal toxicity. </p><p><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> has been given with ESAs for patients with lower-risk MDS.</p><p class="bulletIndent1"><span class="glyph">●</span>An open-label trial randomly assigned 195 evaluable patients with lower-risk, non-del(5q) MDS to <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> plus an ESA versus lenalidomide alone [<a href="#rid36">36</a>]. After four cycles of treatment, the combination achieved a higher rate of major erythroid response compared with lenalidomide alone (28 versus 12 percent, respectively), and the median duration of response was 24 months compared with 13 months. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One-quarter of 23 patients with non-del(5q) MDS who did not have an erythroid response to <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> alone responded to combined treatment with lenalidomide plus an ESA [<a href="#rid37">37</a>]. </p><p></p><p>Treatment, AEs, and outcomes with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> are discussed separately. (See  <a class="medical medical_review" href="/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Lenalidomide'</a>.)</p><p class="headingAnchor" id="H3418418115"><span class="h4">Luspatercept</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126108" href="/d/drug information/126108.html" rel="external">Luspatercept</a> is a transforming growth factor (TGF)-beta antagonist that can reduce transfusion dependence in patients with MDS with ring sideroblasts/<em>SF3B1 </em>mutation. Luspatercept was superior to an ESA for front-line treatment of transfusion-dependent patients with lower-risk MDS in a phase 3 trial; most of the benefit was seen in patients with MDS with ring sideroblasts [<a href="#rid38">38</a>].</p><p><a class="drug drug_general" data-topicid="126108" href="/d/drug information/126108.html" rel="external">Luspatercept</a> is approved by the EMA for treatment of transfusion-dependent anemia in adults with lower-risk MDS with ring sideroblasts/<em>SF3B1 </em>mutation who had an unsatisfactory response to or are ineligible for ESA therapy.</p><p><a class="drug drug_general" data-topicid="126108" href="/d/drug information/126108.html" rel="external">Luspatercept</a> is approved by the FDA for treatment of transfusion-dependent anemia in adults with lower-risk MDS, including ESA-naïve patients.</p><p>Treatment with <a class="drug drug_general" data-topicid="126108" href="/d/drug information/126108.html" rel="external">luspatercept</a> is discussed separately. (See  <a class="medical medical_review" href="/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Luspatercept'</a>.)</p><p class="headingAnchor" id="H547261836"><span class="h4">Imetelstat</span><span class="headingEndMark"> — </span>Imetelstat is an antisense oligonucleotide telomerase inhibitor that can reduce transfusion dependence in selected patients with lower-risk MDS, as discussed separately. (See  <a class="medical medical_review" href="/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)", section on 'Imetelstat'</a>.)</p><p>Imetelstat is not approved by the FDA or the EMA for treatment of MDS.</p><p class="headingAnchor" id="H7196296"><span class="h1">NEUTROPENIA</span><span class="headingEndMark"> — </span>Patients with lower-risk MDS are at increased risk for infections due to reduced numbers of neutrophils and/or granulocyte dysfunction (eg, impaired chemotaxis and microbial killing). </p><p>Patients with an absolute neutrophil count (ANC) &lt;500/microL are at risk for severe, potentially life-threatening infections. However, only 7 percent of patients with lower-risk MDS have ANC &lt;1500/microL, and life-threatening infections are uncommon in the absence of treatment with drugs that worsen neutropenia [<a href="#rid5">5</a>]. Bacterial infections predominate in this setting (especially those involving skin), but fungal, viral, and mycobacterial infections can occur, especially in patients treated with immunosuppressive agents [<a href="#rid39">39</a>]. Risk factors for infections in hospitalized patients with MDS include higher-risk MDS, ANC &lt;500/microL, and chronic obstructive pulmonary disease [<a href="#rid40">40</a>].</p><p>Our approach to management of neutropenia and infectious complications of MDS is consistent with those of the United States National Cancer Center Network (NCCN) and the European Society of Medical Oncology (ESMO). (See <a class="local">'Society guideline links'</a> below.)</p><p>Management of infections in patients with MDS includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutropenic fever</strong> – Patients with ANC &lt;500/microL and fever or other infectious findings must be evaluated urgently. Empiric antibacterial therapy should be administered immediately after blood cultures have been obtained (and before other investigations have been completed). Granulocyte-colony stimulating factor (G-CSF) can be added to antimicrobial agents in the setting of neutropenic fever.</p><p></p><p class="bulletIndent1">Evaluation of febrile neutropenia and empiric antibiotic therapy are discussed separately. (See  <a class="medical medical_review" href="/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever"</a> and  <a class="medical medical_review" href="/d/html/1400.html" rel="external">"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic neutropenia</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Granulocyte-colony stimulating factor</strong> – <a class="drug drug_general" data-topicid="8446" href="/d/drug information/8446.html" rel="external">Filgrastim</a>, pegylated filgrastim, and biosimilars can improve neutropenia, but there is no evidence that routine prophylactic administration in the absence of an infection has an impact on survival or other outcomes in patients with MDS. </p><p></p><p class="bulletIndent2">G-CSF can be considered in patients with recurrent or resistant infections. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prophylactic antibiotics</strong> – There is no demonstrated role for routine antimicrobial prophylaxis in patients with MDS, whether they are neutropenic or not.</p><p></p><p class="bulletIndent2">Clinical judgment should inform a decision to use prophylactic antimicrobials in patients receiving treatments (eg, <a class="drug drug_general" data-topicid="8797" href="/d/drug information/8797.html" rel="external">azacitidine</a>, <a class="drug drug_general" data-topicid="8855" href="/d/drug information/8855.html" rel="external">decitabine</a>, <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a>) that can cause neutropenia and prior to invasive surgical or dental procedures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccinations</strong> – Patients with MDS should be vaccinated to reduce the risk of certain infections.</p><p></p><p class="bulletIndent1">Patients with MDS can receive killed or recombinant immunizations, but live vaccines should generally <strong>not</strong> be given to immunocompromised individuals. </p><p></p><p class="bulletIndent1">Specific recommendations regarding immunizations for patients with cancer and other immunocompromised conditions  (<a class="graphic graphic_figure graphicRef62130" href="/d/graphic/62130.html" rel="external">figure 1</a>) are discussed separately. (See  <a class="medical medical_review" href="/d/html/3899.html" rel="external">"Immunizations in adults with cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Suspected viral reactivation</strong> – Immunocompromised patients, including those with MDS, may experience reactivation of herpes simplex or varicella-zoster virus. Early institution of treatment with antivirals should be provided for patients suspected of herpes virus reactivation. (See  <a class="medical medical_review" href="/d/html/8293.html" rel="external">"Treatment of herpes zoster"</a>.)</p><p></p><p class="headingAnchor" id="H2104237"><span class="h1">THROMBOCYTOPENIA</span><span class="headingEndMark"> — </span>Patients with MDS are at increased risk for bleeding due to thrombocytopenia, qualitative platelet disorders, and/or disorders of coagulation. Management of bleeding is guided by the underlying cause, as described separately. (See  <a class="medical medical_review" href="/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a>.)</p><p>Platelets &lt;50,000/microL are seen in one-third of patients with lower-risk MDS [<a href="#rid5">5</a>]. </p><p>Our approach to managing bleeding in the patient with MDS is similar to those of the American Society for Clinical Oncology (ASCO)  (<a class="graphic graphic_table graphicRef115892" href="/d/graphic/115892.html" rel="external">table 2</a>) and the Association for the Advancement of Blood and Biotherapies (AABB) [<a href="#rid41">41,42</a>].</p><p class="headingAnchor" id="H3623712755"><span class="h2">Platelet transfusion</span><span class="headingEndMark"> — </span>Platelet transfusions are the mainstay of bleeding management in bleeding patients with either quantitative or qualitative (ie, functional) platelet abnormalities. </p><p>Prophylactic platelet transfusions are routinely given to patients with platelets &lt;10,000/microL. Many clinicians administer platelet transfusions at a higher platelet count (eg, 20,000/microL) for patients with active bleeding, fever, severe infection, pulmonary compromise, coagulopathy, or neurologic events.</p><p><a class="drug drug_general" data-topicid="8561" href="/d/drug information/8561.html" rel="external">Aminocaproic acid</a> or other antifibrinolytic agents may be considered for bleeding refractory to platelet transfusions or for those with profound, refractory thrombocytopenia [<a href="#rid43">43</a>]. </p><p>Further discussion of platelet transfusion and other supportive care for bleeding is presented separately. (See  <a class="medical medical_review" href="/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Leukemia, chemotherapy, and HSCT'</a>.)</p><p class="headingAnchor" id="H1421520231"><span class="h2">Refractory bleeding</span><span class="headingEndMark"> — </span>For patients with platelets ≤20,000/microL and clinical bleeding who do not respond to platelet transfusions or <a class="drug drug_general" data-topicid="8561" href="/d/drug information/8561.html" rel="external">aminocaproic acid</a>, we suggest treatment with a thrombopoietin (TPO) mimetic (ie, <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> or <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a>).</p><p>We generally limit TPO mimetic administration to patients with lower-risk MDS and &lt;5 percent blasts to avoid potentially exacerbating progression to acute myeloid leukemia (AML). Although there is controversy about whether TPO mimetics can accelerate progression to AML, a meta-analysis that evaluated trials of a TPO versus placebo found no clear evidence of a difference in mortality or premature progression to AML [<a href="#rid44">44</a>].</p><p>Either <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> or <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> can decrease bleeding, reduce platelet transfusions, and aid timely administration of MDS treatments, but no prospective trial has directly compared these TPO mimetics in this setting.</p><p>Neither <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> nor <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> is approved by the US Food and Drug Administration or the European Medicines Agency for use with MDS. </p><p>Details of administration and adverse effects (AEs) with TPO mimetics are presented separately. (See  <a class="medical medical_review" href="/d/html/6671.html" rel="external">"Clinical applications of thrombopoietic growth factors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Romiplostim</strong> – <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">Romiplostim</a> is a "peptibody" that is administered 1 to 10 mcg/kg by subcutaneous injection weekly, and it is associated with improved platelet counts in one-half of patients with lower-risk MDS. In patients with lower-risk MDS, better response to romiplostim was associated with baseline TPO levels &lt;500 pg/mL and a limited history of platelet transfusions [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A study reported improved platelet counts and a trend to fewer bleeding events with <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> compared with placebo in patients with lower-risk MDS, but conclusions are limited because the study was terminated early [<a href="#rid46">46</a>]. Among the 56 patients who completed the 58-week study, romiplostim decreased the number of platelet transfusions (relative risk [RR] 0.71 [95% CI 0.61-0.82]) in patients with baseline platelet counts &lt;20,000/microL, and there was a trend toward fewer clinically significant bleeding events. The study was closed early by the data monitoring committee when interim analysis suggested an increased risk for progression to AML, but with a five-years follow-up, there was no difference in overall survival (OS) or progression to AML between treatment groups [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among 77 patients with lower-risk MDS and a median platelet count of 25,000/microL, <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> was associated with 42 percent platelet response with a median duration of 340 days; neutrophil and erythroid responses were observed in 4 and 9 percent of patients, respectively [<a href="#rid48">48</a>]. A transient rise in circulating blasts (&gt;10 percent) was noted in 8 percent of patients; the increase in blasts was reversible with romiplostim interruption, but two patients progressed to AML. No association has been found between TPO level and response to romiplostim. In another study, romiplostim was associated with 55 percent platelet response in patients with lower-risk MDS and thrombocytopenia, but 15 percent had a transient rise in marrow and/or circulating peripheral blasts that reversed after drug discontinuation [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">Romiplostim</a> was safe and associated with trends toward fewer bleeding events and higher platelet counts in patients treated with <a class="drug drug_general" data-topicid="8855" href="/d/drug information/8855.html" rel="external">decitabine</a> [<a href="#rid50">50</a>] and with fewer dose reductions/delays due to thrombocytopenia in patients treated with <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eltrombopag</strong> – <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">Eltrombopag</a> is an orally available nonpeptide TPO receptor agonist. Initial dosing of eltrombopag varies, but lower starting doses should be used in patients of Asian descent. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">Eltrombopag</a> was associated with fewer bleeding episodes and better platelet response compared with placebo in a study of patients with lower-risk MDS [<a href="#rid52">52</a>]. Eltrombopag was associated with fewer bleeding events (14 versus 42 percent) but more grade ≥3 AEs (46 versus 16 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">Eltrombopag</a> was well tolerated, and it was associated with 44 percent hematologic response in a study of 25 patients; the dose was escalated from 50 mg/day to a maximum of 150 mg/day over a period of 16 weeks [<a href="#rid53">53</a>]. Six patients had disease progression that was not associated with expansion of mutated clones, and no patient progressed to AML while on study. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Among 28 patients who received <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> in combination with a hypomethylating agent (HMA) after not responding to &gt;4 cycles of HMA therapy, improved platelet counts were reported in 11 percent; median OS was 12 months and 11 percent had progressive disease [<a href="#rid54">54</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with higher-risk MDS, <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> was associated with fewer clinically relevant thrombocytopenia-related events, but there was no difference in platelet transfusion independence or hematologic parameters [<a href="#rid55">55</a>]. </p><p></p><p class="headingAnchor" id="H1063344"><span class="h1">TRANSFORMATION TO ACUTE MYELOID LEUKEMIA</span><span class="headingEndMark"> — </span>Patients with MDS have variable rates of transformation to acute myeloid leukemia (AML) that are closely associated with the MDS prognostic category  (<a class="graphic graphic_table graphicRef85832" href="/d/graphic/85832.html" rel="external">table 3</a>). </p><p>The categorization and distinction between MDS and AML differ between the two contemporary systems for diagnosis and classification of hematologic malignancies [<a href="#rid56">56,57</a>], as discussed separately. (See  <a class="medical medical_review" href="/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms", section on 'Myeloid neoplasms'</a>.) </p><p>The decision of when and with what to treat a patient with AML-directed therapy is individualized and is discussed separately. (See  <a class="medical medical_review" href="/d/html/4525.html" rel="external">"Acute myeloid leukemia: Induction therapy in medically fit adults"</a> and  <a class="medical medical_review" href="/d/html/4530.html" rel="external">"Acute myeloid leukemia: Management of medically unfit adults"</a>.)</p><p class="headingAnchor" id="H1576631439"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Patients with MDS should be followed to monitor hematologic parameters, clinical manifestations, and disease progression. The schedule and protocol for follow-up should be individualized based on the severity of cytopenias, degree of symptoms, and concerns on the part of the patient and clinician. </p><p>Patients with hematologic complications of lower-risk MDS are followed with clinical evaluation and complete blood count with differential leukocyte count. We assess symptoms, transfusion needs, trends of blood counts, and quality of life every two to six months, according to clinical judgment.</p><p>Outside of a clinical study, we do not perform routine bone marrow examinations unless there is evidence of worsening cytopenias or other indications of disease progression.</p><p class="headingAnchor" id="H3549935031"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116777.html" rel="external">"Society guideline links: Myelodysplastic syndromes"</a>.)</p><p class="headingAnchor" id="H2105714"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16328.html" rel="external">"Patient education: Myelodysplastic syndromes (MDS) (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15854.html" rel="external">"Patient education: Autologous bone marrow transplant (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/692.html" rel="external">"Patient education: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/686.html" rel="external">"Patient education: Hematopoietic cell transplantation (bone marrow transplantation) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2106062"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Management of hematologic complications is needed for all patients with myelodysplastic syndromes/neoplasms (MDS). Most morbidity and deaths in patients with lower-risk MDS are related to cytopenias rather than progression to acute myeloid leukemia (AML).</p><p></p><p class="bulletIndent1">Diagnosis, classification, and risk stratification of MDS are discussed separately. (See  <a class="medical medical_review" href="/d/html/4492.html" rel="external">"Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS)"</a> and  <a class="medical medical_review" href="/d/html/15775.html" rel="external">"Prognosis of myelodysplastic neoplasms/syndromes (MDS) in adults"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Clinical and laboratory evaluation is discussed above. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic anemia</strong> – We do not treat anemia based on the level of hemoglobin (Hb) alone (ie, without anemia-associated symptoms). However, we transfuse red blood cells (RBCs) if bleeding, hemolysis, or declining Hb suggests that the patient will soon become symptomatic, especially in those with comorbid conditions. (See <a class="local">'Management of asymptomatic patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic</strong> <strong>anemia</strong> – We stratify management of anemia in symptomatic patients based on the level of serum erythropoietin (EPO). (See <a class="local">'Symptomatic patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serum erythropoietin ≤500 mU/mL</strong> – For symptomatic patients with serum EPO ≤500 mU/mL, we recommend <a class="drug drug_general" data-topicid="9410" href="/d/drug information/9410.html" rel="external">epoetin alfa</a> or <a class="drug drug_general" data-topicid="8662" href="/d/drug information/8662.html" rel="external">darbepoetin alfa</a> rather than RBC transfusions alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Serum erythropoietin ≤500 mU/mL'</a> above.)</p><p></p><p class="bulletIndent1">Treatment with either agent is acceptable, based on similar efficacy and adverse effects (AEs). Dosing  (<a class="graphic graphic_table graphicRef59470" href="/d/graphic/59470.html" rel="external">table 1</a>) and AEs are discussed above. (See <a class="local">'Administration and toxicity'</a> above.)</p><p></p><p class="bulletIndent1">Consequences of chronic RBC transfusion therapy are discussed above. (See <a class="local">'Red blood cell transfusions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Response assessment</strong> – We assess response after six to eight weeks of erythropoiesis-stimulating agent (ESA) therapy and treat for ≥16 weeks before concluding therapy is ineffective; treatment is discontinued if no response is observed after six months. </p><p></p><p class="bulletIndent2">We consider reduced transfusion requirements, Hb 10 to 12 g/dL, or Hb rise by ≥1.5 gm/dL an adequate response. (See <a class="local">'Response to erythropoiesis-stimulating agent therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Adequate response</strong> – Continue treatment and adjust the dose or treatment interval to minimize transfusions and maintain Hb 10 to 12 g/dL. (See <a class="local">'Adequate response to erythropoiesis-stimulating agent'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Inadequate response</strong> – For an inadequate response after ≥16 weeks of treatment, we suggest adding granulocyte-colony stimulating factor (G-CSF) to the ESA (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Inadequate response to erythropoiesis-stimulating agent'</a> above.) </p><p></p><p class="bulletIndent3">Management of patients with an inadequate response ESA plus G-CSF is discussed separately. (See  <a class="medical medical_review" href="/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythropoietin &gt;500 mU/mL</strong> – Management is guided by the likelihood of responding to immunosuppressive therapy (IST), as described above. (See <a class="local">'Assess likelihood of response to immunosuppressive therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Likely to respond to immunosuppressive therapy</strong> – We suggest IST using <a class="drug drug_general" data-topicid="9107" href="/d/drug information/9107.html" rel="external">horse antithymocyte globulin</a>, with or without cyclosporin A, and with or without <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Likely to respond to immunosuppressive therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unlikely to respond</strong> – Management is guided by MDS prognostic score. (See  <a class="medical medical_review" href="/d/html/4542.html" rel="external">"Treatment of lower-risk myelodysplastic syndromes (MDS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neutropenia</strong> – There is no evidence that routine prophylactic G-CSF or antibiotics benefit asymptomatic patients with lower-risk MDS. (See <a class="local">'Neutropenia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombocytopenia</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Platelet transfusions</strong> – Transfusions are the mainstay of managing bleeding in patients with severe thrombocytopenia. (See <a class="local">'Platelet transfusion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory bleeding</strong> – For thrombocytopenic patients with continued bleeding after platelet transfusions and antifibrinolytic agents or with severe thrombocytopenia refractory to platelet transfusion, we suggest <a class="drug drug_general" data-topicid="9493" href="/d/drug information/9493.html" rel="external">romiplostim</a> or <a class="drug drug_general" data-topicid="9051" href="/d/drug information/9051.html" rel="external">eltrombopag</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Either agent can reduce bleeding and improve platelet counts, and there is no persuasive evidence of increased progression to AML. (See <a class="local">'Refractory bleeding'</a> above.)</p><p></p><p class="headingAnchor" id="H1924219715"><span class="h1">ACKNOWLEDGMENTS</span></p><p>The UpToDate editorial staff acknowledges Elihu H Estey, MD, who contributed as an author for this topic review.</p><p>The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as author on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Steensma DP. Myelodysplastic Syndromes: Diagnosis and Treatment. Mayo Clin Proc 2015; 90:969.</a></li><li><a class="nounderline abstract_t">Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010; 116:4045.</a></li><li><a class="nounderline abstract_t">Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010; 28:4996.</a></li><li><a class="nounderline abstract_t">Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122:2943.</a></li><li><a class="nounderline abstract_t">Fenaux P, Haase D, Santini V, et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆. Ann Oncol 2021; 32:142.</a></li><li><a class="nounderline abstract_t">Greenberg PL, Stone RM, Al-Kali A, et al. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. J Natl Compr Canc Netw 2022; 20:106.</a></li><li><a class="nounderline abstract_t">Smith SW, Sato M, Gore SD, et al. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica 2012; 97:15.</a></li><li><a class="nounderline abstract_t">Park S, Greenberg P, Yucel A, et al. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. Br J Haematol 2019; 184:134.</a></li><li><a class="nounderline abstract_t">Jädersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26:3607.</a></li><li><a class="nounderline abstract_t">Garelius HK, Johnston WT, Smith AG, et al. Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. J Intern Med 2017; 281:284.</a></li><li><a class="nounderline abstract_t">Gotlib J, Lavori P, Quesada S, et al. A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol 2009; 84:15.</a></li><li><a class="nounderline abstract_t">Park S, Fenaux P, Greenberg P, et al. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis. Br J Haematol 2016; 174:730.</a></li><li><a class="nounderline abstract_t">Stasi R, Abruzzese E, Lanzetta G, et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005; 16:1921.</a></li><li><a class="nounderline abstract_t">Mannone L, Gardin C, Quarre MC, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 2006; 133:513.</a></li><li><a class="nounderline abstract_t">Villegas A, Arrizabalaga B, Fernández-Lago C, et al. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin 2011; 27:951.</a></li><li><a class="nounderline abstract_t">Kelaidi C, Park S, Sapena R, et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia 2013; 27:1283.</a></li><li><a class="nounderline abstract_t">Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008; 111:574.</a></li><li><a class="nounderline abstract_t">Platzbecker U, Fenaux P, Adès L, et al. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood 2019; 133:1020.</a></li><li><a class="nounderline abstract_t">Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009; 114:2393.</a></li><li><a class="nounderline abstract_t">Balleari E, Rossi E, Clavio M, et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol 2006; 85:174.</a></li><li><a class="nounderline abstract_t">Platzbecker U, Symeonidis A, Oliva EN, et al. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia 2017; 31:1944.</a></li><li><a class="nounderline abstract_t">Fenaux P, Santini V, Spiriti MAA, et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Leukemia 2018; 32:2648.</a></li><li><a class="nounderline abstract_t">Casadevall N, Durieux P, Dubois S, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004; 104:321.</a></li><li><a class="nounderline abstract_t">Kelaidi C, Beyne-Rauzy O, Braun T, et al. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol 2013; 92:621.</a></li><li><a class="nounderline abstract_t">Gabrilove J, Paquette R, Lyons RM, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008; 142:379.</a></li><li><a class="nounderline abstract_t">Oliva EN, Nobile F, Alimena G, et al. Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life. Leuk Lymphoma 2010; 51:1007.</a></li><li><a class="nounderline abstract_t">Nilsson-Ehle H, Birgegård G, Samuelsson J, et al. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions. Eur J Haematol 2011; 87:244.</a></li><li><a class="nounderline abstract_t">Mundle S, Lefebvre P, Vekeman F, et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 2009; 115:706.</a></li><li><a class="nounderline abstract_t">Hellström-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92:68.</a></li><li><a class="nounderline abstract_t">Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999; 131:401.</a></li><li><a class="nounderline abstract_t">Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100:1570.</a></li><li><a class="nounderline abstract_t">Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med 2017; 376:1540.</a></li><li><a class="nounderline abstract_t">Assi R, Garcia-Manero G, Ravandi F, et al. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 2018; 124:4192.</a></li><li><a class="nounderline abstract_t">Tanasijevic AM, Revette A, Klepin HD, et al. Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. Leuk Lymphoma 2020; 61:2900.</a></li><li><a class="nounderline abstract_t">Angelucci E, Li J, Greenberg P, et al. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. Ann Intern Med 2020; 172:513.</a></li><li><a class="nounderline abstract_t">List AF, Sun Z, Verma A, et al. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. J Clin Oncol 2021; 39:1001.</a></li><li><a class="nounderline abstract_t">Komrokji RS, Lancet JE, Swern AS, et al. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood 2012; 120:3419.</a></li><li><a class="nounderline abstract_t">Platzbecker U, Della Porta MG, Santini V, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet 2023; 402:373.</a></li><li><a class="nounderline abstract_t">Toma A, Fenaux P, Dreyfus F, Cordonnier C. Infections in myelodysplastic syndromes. Haematologica 2012; 97:1459.</a></li><li><a class="nounderline abstract_t">Sullivan LR, Sekeres MA, Shrestha NK, et al. Epidemiology and risk factors for infections in myelodysplastic syndromes. Transpl Infect Dis 2013; 15:652.</a></li><li><a class="nounderline abstract_t">Schiffer CA, Bohlke K, Delaney M, et al. Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2018; 36:283.</a></li><li><a class="nounderline abstract_t">Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015; 162:205.</a></li><li><a class="nounderline abstract_t">Antun AG, Gleason S, Arellano M, et al. Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. Cancer 2013; 119:3784.</a></li><li><a class="nounderline abstract_t">Dodillet H, Kreuzer KA, Monsef I, Skoetz N. Thrombopoietin mimetics for patients with myelodysplastic syndromes. Cochrane Database Syst Rev 2017; 9:CD009883.</a></li><li><a class="nounderline abstract_t">Sekeres MA, Giagounidis A, Kantarjian H, et al. Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes. Br J Haematol 2014; 167:337.</a></li><li><a class="nounderline abstract_t">Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer 2014; 120:1838.</a></li><li><a class="nounderline abstract_t">Kantarjian HM, Fenaux P, Sekeres MA, et al. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol 2018; 5:e117.</a></li><li><a class="nounderline abstract_t">Kubasch AS, Giagounidis A, Metzgeroth G, et al. Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO. Leukemia 2022; 36:2519.</a></li><li><a class="nounderline abstract_t">Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010; 28:437.</a></li><li><a class="nounderline abstract_t">Greenberg PL, Garcia-Manero G, Moore M, et al. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma 2013; 54:321.</a></li><li><a class="nounderline abstract_t">Wang ES, Lyons RM, Larson RA, et al. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol 2012; 5:71.</a></li><li><a class="nounderline abstract_t">Oliva EN, Riva M, Niscola P, et al. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS). J Clin Oncol 2023; 41:4486.</a></li><li><a class="nounderline abstract_t">Vicente A, Patel BA, Gutierrez-Rodrigues F, et al. Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome. Haematologica 2020; 105:2785.</a></li><li><a class="nounderline abstract_t">Swaminathan M, Borthakur G, Kadia TM, et al. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma 2019; 60:2207.</a></li><li><a class="nounderline abstract_t">Mittelman M, Platzbecker U, Afanasyev B, et al. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial. Lancet Haematol 2018; 5:e34.</a></li><li><a class="nounderline abstract_t">Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.</a></li><li><a class="nounderline abstract_t">Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36:1703.</a></li></ol></div><div id="topicVersionRevision">Topic 15776 Version 51.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26141335" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Myelodysplastic Syndromes: Diagnosis and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20974674" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20975064" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23980065" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33221366" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35130502" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : NCCN Guidelines®Insights: Myelodysplastic Syndromes, Version 3.2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22102702" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30549002" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559873" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27926979" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19006226" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27214305" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16166176" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16681638" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21381892" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23370672" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17940203" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30404811" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19564636" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16408206" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28626220" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29895954" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-αin anemic patients with low-risk MDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15054036" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23358617" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18540943" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20367566" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21623919" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19152429" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9639501" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10498555" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12176872" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28423296" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30307606" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32667230" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203980" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33439748" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22936658" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37311468" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22733024" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Infections in myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24010918" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Epidemiology and risk factors for infections in myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29182495" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25383671" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Platelet transfusion: a clinical practice guideline from the AABB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23921838" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28962071" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Thrombopoietin mimetics for patients with myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25039607" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24706489" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29396092" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36071100" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008626" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22906162" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23190430" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37294914" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33256377" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30773968" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29241762" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
